MyFinsight
Home
Blog
About
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$191K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Trade receivables
Inventories
Net income
Others
Negative Cash Flow Breakdown
Accounts payable
Accrued expenses
Repurchase of common stock
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
963
6,318
4,132
4,578
Depreciation of leasehold improvements and equipment
117
116
139
157
Amortization of intangibles
174
175
60
38
Noncash lease expense
179
173
169
496
Gain on sale of operating segment
-3
4,784
-
-
Share-based compensation expense
1,723
1,716
1,748
1,756
Loss on disposal of leasehold improvements and equipment
-23
0
0
0
Allowance for (recovery of) credit losses
-66
85
27
-12
Reversal of previously accrued royalties and license maintenance fees
-
-
0
-
Gain on settlement of royalty obligation
-
-
1,983
-
Interest accretion on deferred consideration
115
114
38
-
Non-cash financing costs
-13
-12
-18
-15
Trade receivables
-4,554
3,412
1,262
-1,162
Inventories
-3,376
3,573
2,036
4,385
Implementation costs for cloud computing arrangement
0
30
0
0
Prepaid expenses and other assets
350
169
-746
-87
Accounts payable
-3,838
2,481
-1,946
-938
Accrued expenses
-3,780
-101
958
1,319
Deferred revenue
-138
-102
0
0
Customer deposits and other
-50
-13
107
-16
Operating lease liabilities
-247
-241
-236
-233
Deferred consideration liability
1
41
-
-
Net cash provided by operating activities
2,772
-1,194
679
3,692
Purchases of leasehold improvements and equipment
89
61
101
191
Proceeds from sale of operating segment
0
5,800
-
-
Proceeds from the sale of leasehold improvements and equipment, net
-
-
0
0
Transaction costs from sale of operating segment
3
494
-
-
Net cash provided by / (used in) investing activities
-92
5,245
-101
-24
Payment of deferred consideration
0
47
-
-
Proceeds from exercise of stock options
206
111
228
152
Proceeds from issuance of common stock from espp
72
-
-
-
Repurchase of common stock
2,767
2,354
251
-
Payment of debt issuance costs
0
0
55
0
Principal payments on finance leases
0
0
2
4
Net cash (used in) / provided by financing activities
-2,489
-2,290
-80
148
Net increase in cash and cash equivalents
191
1,761
498
3,816
Cash and cash equivalents at beginning of period
-
-
-
44,660
Cash and cash equivalents at end of period
-
-
-
64,290
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Trade receivables
-$4,554K
(-794.21%↓ Y/Y)
Inventories
-$3,376K
(-164.75%↓ Y/Y)
Share-based compensation
expense
$1,723K
(-32.77%↓ Y/Y)
Net income
$963K
(-88.90%↓ Y/Y)
Noncash lease expense
$179K
(-46.08%↓ Y/Y)
Amortization of intangibles
$174K
(132.00%↑ Y/Y)
Depreciation of leasehold
improvements and equipment
$117K
(-62.97%↓ Y/Y)
Interest accretion on
deferred consideration
$115K
Loss on disposal of
leasehold improvements...
-$23K
(-475.00%↓ Y/Y)
Non-cash financing costs
-$13K
(50.00%↑ Y/Y)
Gain on sale of
operating segment
-$3K
Deferred consideration
liability
$1K
Net cash provided by
operating activities
$2,772K
(-69.65%↓ Y/Y)
Canceled cashflow
$8,469K
Net increase in cash
and cash...
$191K
(-98.79%↓ Y/Y)
Canceled cashflow
$2,581K
Accounts payable
-$3,838K
(-174.47%↓ Y/Y)
Accrued expenses
-$3,780K
(-766.97%↓ Y/Y)
Prepaid expenses and
other assets
$350K
(221.53%↑ Y/Y)
Operating lease
liabilities
-$247K
(48.54%↑ Y/Y)
Deferred revenue
-$138K
(-245.26%↓ Y/Y)
Allowance for (recovery
of) credit losses
-$66K
(94.64%↑ Y/Y)
Customer deposits and
other
-$50K
(83.77%↑ Y/Y)
Proceeds from exercise of
stock options
$206K
(-97.00%↓ Y/Y)
Proceeds from issuance of
common stock from espp
$72K
Net cash (used in) /
provided by financing...
-$2,489K
(-136.35%↓ Y/Y)
Net cash provided by
/ (used in)...
-$92K
(44.91%↑ Y/Y)
Canceled cashflow
$278K
Repurchase of common stock
$2,767K
Purchases of leasehold
improvements and equipment
$89K
(-46.71%↓ Y/Y)
Transaction costs from sale
of operating...
$3K
Buy us a coffee